Information Provided By:
Fly News Breaks for May 7, 2018
SRPT
May 7, 2018 | 08:09 EDT
Needham analyst Chad Messer raised his price target on Sarepta to $109 and kept his Buy rating after the company's in-line Q1 results. Messer cites Sarepta's announcing an R&D presentation on June 19th to discuss its "growing pipeline", adding that the company had already promised "at least 2 patients worth of safety and gene expression data from the ongoing microdystrophin gene therapy program". The analyst expects Sarepta stock to reflect investor optimism typically given to early data from gene therapy companies.
News For SRPT From the Last 2 Days
There are no results for your query SRPT